Diabetes Mellitus, Non-Insulin-Dependent
Item
type 2 diabetes
boolean
C0011860 (UMLS CUI [1])
Age | Cardiovascular Diseases | Cerebrovascular Disorders | Peripheral Vascular Diseases | Kidney Failure, Chronic | Chronic heart failure | Risk factors Vascular Diseases
Item
age min. 50 years at screening and concomitant cardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure or chronic heart failure or age min. 60 years at screening and other specified risk factors of vascular disease
boolean
C0001779 (UMLS CUI [1])
C0007222 (UMLS CUI [2])
C0007820 (UMLS CUI [3])
C0085096 (UMLS CUI [4])
C0022661 (UMLS CUI [5])
C0264716 (UMLS CUI [6])
C0035648 (UMLS CUI [7,1])
C0042373 (UMLS CUI [7,2])
Hemoglobin A1c measurement
Item
hba1c: 7.0% or above
boolean
C0474680 (UMLS CUI [1])
Antidiabetics Absent | Antidiabetics Oral Quantity | Insulin, isophane | Insulin Analog Active Long-term | premixed insulin | Combined Modality Therapy
Item
anti-diabetic drug naive or treated with one or more oral anti-diabetic drugs (oads) or treated with human nph insulin or long-acting insulin analogue or premixed insulin, alone or in combination with oad(s)
boolean
C0935929 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0935929 (UMLS CUI [2,1])
C1527415 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0021658 (UMLS CUI [3])
C2825028 (UMLS CUI [4,1])
C0205177 (UMLS CUI [4,2])
C0443252 (UMLS CUI [4,3])
C2069057 (UMLS CUI [5])
C0009429 (UMLS CUI [6])
Diabetes Mellitus, Insulin-Dependent
Item
type 1 diabetes
boolean
C0011854 (UMLS CUI [1])
GLP-1 Receptor Agonist | exenatide | liraglutide | Pramlintide | DPP-4 Inhibitor
Item
use of a glucagon-like peptide-1 (glp-1) receptor agonist (exenatide, liraglutide or other) or pramlintide or any dipeptidyl peptidase 4 (dpp-4) inhibitor within the 3 months prior to screening (trial start)
boolean
C2917359 (UMLS CUI [1])
C0167117 (UMLS CUI [2])
C1456408 (UMLS CUI [3])
C0537551 (UMLS CUI [4])
C3537225 (UMLS CUI [5])
Insulin use | Exception NPH insulin | Exception Insulin Analog Active Long-term | Exception Premixed insulin
Item
use of insulin other than human nph insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. short-term use of other insulin during this period in connection with intercurrent illness is allowed, at investigator's discretion
boolean
C0240016 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0021658 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C2825028 (UMLS CUI [3,2])
C0205177 (UMLS CUI [3,3])
C0443252 (UMLS CUI [3,4])
C1705847 (UMLS CUI [4,1])
C2069057 (UMLS CUI [4,2])